Bayram, E. 2023. 252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study. ESMO OPEN , vol.8 , 101440.

Bayram, E., (2023). 252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study. ESMO OPEN , vol.8, 101440.

Bayram, ERTUĞRUL. "252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study," ESMO OPEN , vol.8, 101440, 2023

Bayram, ERTUĞRUL. "252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study." ESMO OPEN , vol.8, pp.101440, 2023

Bayram, E. (2023) . "252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study." ESMO OPEN , vol.8, p.101440.

@article{article, author={ERTUĞRUL BAYRAM}, title={252P Impact of HER2 expression levels on survival in patients with hormone receptor positive and HER2 negative advanced breast cancer and treated with ribociclib and palbociclib in combination with endocrine therapy: A real-life data, Turkish Oncology Group study}, journal={ESMO OPEN}, year=2023, pages={101440} }